To improve the program to provide for priority review of human drug applications to encourage treatment for agents that present national security threats.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
The bill provides extension and expansion of medical countermeasure priority review voucher program Subsection (a)(4) of section 565A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. It relies on definition changes, appropriations, reporting requirements, and compliance mandates. The main policy areas are Energy, Healthcare Consumers, Environment, and Healthcare.
Who Benefits and How
Patients and health care consumers affected by the bill could gain revenue opportunities, Natural gas companies and customers affected by the bill could gain revenue opportunities, and Environmental and public health interests affected by the bill could gain revenue opportunities.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties.
Key Provisions
- Provides extension and expansion of medical countermeasure priority review voucher program Subsection (a)(4) of section 565A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill provides extension and expansion of medical countermeasure priority review voucher program Subsection (a)(4) of section 565A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
Key Policy Areas
Energy, Healthcare Consumers, Environment, Healthcare
Primary Purpose
The bill provides extension and expansion of medical countermeasure priority review voucher program Subsection (a)(4) of section 565A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
Policy Domains
Whole bill
Identified Gains
- Patients and health care consumers affected by the bill
- Natural gas companies and customers affected by the bill
- Environmental and public health interests affected by the bill
- Energy producers and energy supply-chain firms affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
Sponsors
Legislative Progress
IntroducedMs. Ernst introduced the following bill; which was read twice …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology